Prof Arnold Vulto speaks to ecancer at the 2019 Biosimilars Educational Advanced Masterclass for Pharmacists (P-BEAM) in Zurich about the effect of infliximab, rituximab and adalimumab on immunogenicity.

He mentions that these reference products have high antibody titres and are highly similar to their respective biosimilar.

Prof Vulto emphasises that the immunogenicity of these biosimilars is no different from the reference product.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

If you would like to learn more about biosimilar medicines, please visit our free e-learning modules here.